Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.
Apr 12, 2018
0
7
Alectinib provides longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer (NSCLC), according to results from the ALEX trial presented at the ELCC 2018 (European Lung Cancer Congress) in Geneva, ...
Apr 12, 2018
0
5
Non-small-cell lung cancer, the most common type of lung cancer, is the leading cause of cancer death in the U.S. A new study suggests that about 1 in 4 cases, those driven by the KRAS oncogene, could be successfully treated ...
Apr 2, 2018
0
56
Scientists from the Universities of Bristol and Parma, Italy, have used molecular simulations to understand resistance to osimertinib - an anticancer drug used to treat types of lung cancer.
Feb 12, 2018
0
63
(HealthDay)—Nivolumab treatment for non-small-cell lung cancer may induce successful depletion of HIV reservoir, according to a letter to the editor published online Dec. 1 in the Annals of Oncology.
Dec 4, 2017
0
18
With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online ...
Oct 26, 2017
0
1
(HealthDay)—The prognostic value of pathologic nodal (pN) stratification depends on the thoroughness of nodal examination in the staging of non-small-cell lung cancer, according to a study published online Sept. 28 in JAMA ...
Sep 29, 2017
0
15
Osimertinib improves progression-free survival by 54% compared to standard first line therapy in patients with EGFR mutated non-small-cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented ...
Sep 11, 2017
0
0
Daily aspirin use—known to reduce the risk of colon cancer—could also make the disease harder to treat if it does occur, researchers reported Wednesday.
Sep 6, 2017
0
133
Lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors may be at increased risk of adverse events after receiving the seasonal influenza vaccination, according to the first study measuring this effect.
Apr 26, 2017
0
3
